400777-06-2

Usage

Uses

3-Amino-2-chloro-6-iodopyridine is a pyridine based building block used in organic synthesis.

InChI:InChI=1/C5H4ClIN2/c6-4-2-1-3(8)5(7)9-4/h1-2H,8H2

Upstream product

• 5350-93-6 6-Chloro-pyridin-3-ylamine 

Downstream Products

• 351227-36-6 Methyl 5-Chloro-2-(4-chlorophenyl)-1H-pyrrolo[3,2-b]pyridine-3-propanoate 
• 4943-67-3 ?5-methyl-1H-pyrrolo[3,2-b]pyridine 
• 1000343-73-6 3-bromo-5-methyl-1H-pyrrolo[3,2-b]pyridine 
• 1073182-90-7 3-amino-4-bromo-6-chloropyridine-2-carboxylic acid 
• 866807-27-4 3-amino-6-chloro-pyridine-2-carboxylic acid 
• 866807-26-3 methyl 3-amino-6-chloropicolinate 
• 1394003-98-5 6-chloro-1,5-naphthyridin-2(1H)-one 
• 1621886-94-9 2-(4-fluorophenyl)-5-(10-fluoropyrido[3',2':4,5]pyrimido[1,6-a]indol-2-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1621886-90-5 2-(4-fluorophenyl)-5-(1 1-fluoropyrido[3',2’:4,5]pyrimido[1,6-a]indol-2-yl)-N-methyl-6-(N-methylmethylsulfonamido)pyrazolo[1,5-a]pyridine-3-carboxamide 
• 1621886-89-2 2-(4-fluorophenyl)-5-(11-fluoropyrido[3',2':4,5]pyrimido[1,6-a]indol-2-yl)-N-methyl-6-(N-methylmethylsulfonamido)-2H-indazole-3-carboxamide 
• 1621886-88-1 2-(4-fluorophenyl)-5-(11-fluoropyrido[3',2':4,5]pyrimido[1,6-a]indol-2-yl)-N-methyl-6-(N-methylmethylsulfonamido)furo[2,3-b]pyridine-3-carboxamide 
• 1621886-84-7 2-(4-fluorophenyl)-5-(11-fluoropyrido[3',2':4,5]pyrimido[1,6-a]indol-2-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1621886-83-6 2-(2,4-difluorophenyl)-5-(11-fluoropyrido[3',2':4,5 ]pyrimido[1,6-a]indol-2-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 

Relevant academic research and scientific papers

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

TRIAZINE DERIVATIVE HAVING EGFR INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF

Disclosed are a triazine derivative having EGFR inhibitory activity, a preparation method therefor and use thereof. In particular, disclosed are an EGFR inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, use thereof for preparing the EGFR inhibitor, and use thereof in preparing medicaments for treating and/or preventing cancers, tumors or metastatic diseases at least partially related to insertion, deletion or other mutation of EGFR exon 20, and in particular use thereof in preparing medicaments for treating and/or preventing hyperproliferative diseases and diseases inducing cell death disorders. The definition of each substituent of formula (I) is the same as that in the description.

HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and a good inhibitory activity against autotaxin (ATX).

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Compounds of Formula I and the pharmaceutically acceptable salts thereof are provided as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Bicarbazole containing compounds for OLED

The present disclosure generally relates to novel compounds containing carbazole and triazine with different number of phenyl units attached to its core. In particular, the disclosure relates to compositions and/or devices comprising these compounds as ho

DONOR-ACCEPTOR COMPOUNDS WITH NITROGEN CONTAINING HETEROPOLYAROMATICS AS THE ELECTRON ACCEPTOR

Disclosed is a light emitting substance that is used as an emitter in an organic light emitting diode. The light emitting substance includes a donor-acceptor compound having a high triplet energy heteropoly aromatic system. In other words, the donor-acceptor compound includes dibenzofuran, dibenzothiophene, and dibenzoselenophene that are electron acceptors and have multiple nitrogen atoms in one ring. The compound is represented by Chemical Formula 1 below.COPYRIGHT KIPO 2015

New bicyclic compounds as crac channel modulators

The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

NEW CRTH2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

New CRTh2 antagonists

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

AZAINDOLE DERIVATIVES AS CFTR MODULATORS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.